Respiratory

The authors said the findings bring new urgency to efforts by policy makers, school officials, community leaders, and others to educate the public about the link between smoking and coronavirus disease 2019 (COVID-19).

A risk prediction model based on high-resolution computed tomography (HRCT) variables outperformed other models when predicting mortality among patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

According to a new study, patients with connective tissue disease-associated interstitial disease (CTD-ILD) had significantly higher mortality rates and worse 10-year survival rates than patients who did not develop the complication.

The race for a coronavirus disease 2019 (COVID-19) vaccine is one of the most urgent public health challenges, with multiple vaccine candidates entering phase 3 trials and case counts around the world steadily climbing. MJH Life Sciences™ will host a free webinar with the top minds in infectious disease, virology, and vaccinology to discuss the latest trial information on vaccines.

Two experimental vaccines, one from AstraZeneca and the other from CanSino Biologics, have shown promising results against coronavirus disease 2019 (COVID-19) in a phase 1/2 trial and a phase 2 trial. Results for both were published in The Lancet.

The effect of chronic fibrosing ILD with progressive phenotype on personal relationships with friends and family.

Other respiratory diseases, such as chronic obstructive pulmonary disease and asthma, also have seasonal variations, but the impact of such variation on interstitial lung disease (ILD) is poorly understood.

Concerns and precautions for a patient living with chronic fibrosing ILD with progressive phenotype during the coronavirus pandemic.

Investigators used death certificate data to determine the annual average decline of deaths attributed to systemic sclerosis.

Insurance coverage concerns and difficulties while seeking care for chronic fibrosing ILD with progressive phenotype.

States hardest hit by resurgent cases of coronavirus disease 2019 (COVID-19) have taken steps to either halt or reverse plans to reopen economies; study findings suggest patients with asthma are no more likely than those without asthma to be hospitalized for COVID-19; the Trump administration plans to adopt a decades-old testing strategy called pooled testing that would expand testing efforts in the United States.

The management of chronic fibrosing ILD with progressive phenotype through immunosuppressants and oxygen is examined as well as the effect on lifestyle.